Adrenomedullin and glucagon-like peptide-1 have additive effects on food intake in mice

Esben M. Bech; Kristoffer Voldum-clausen; Søren L. Pedersen; Katrine Fabricius; Lise C.B. Rudkjær; Henrik H. Hansen; Jacob Jelsing

doi:10.1016/j.biopha.2018.10.040

Adrenomedullin and glucagon-like peptide-1 have additive effects on food intake in mice

Esben M. Bech, Kristoffer Voldum-clausen, Søren L. Pedersen, Katrine Fabricius, Lise C.B. Rudkjær, Henrik H. Hansen, Jacob Jelsing

Department of Chemistry

5 Citations (Scopus)

Abstract

Adrenomedullin (ADM) is a vasoactive peptide expressed in several peripheral organs and known primarily for its beneficial vasoactive effects. However, ADM is also known to inhibit insulin secretion, and central administration of ADM has been shown to elicit anorexigenic effects. Here, we investigated if peripheral co-administration of ADM and glucagon-like peptide 1 (GLP-1) could subdue the hypoglycaemic effects of ADM while enhancing its anorectic properties. The effects of mono- and combination therapy of ADM and GLP-1 on appetite regulation and glucose homeostasis were assessed acutely in male NMRI mice for 12 h, while effects on glucose homeostasis were assessed by oral glucose tolerance tests (OGTT). While the monotherapy with GLP-1 and ADM resulted in modest anorexigenic effects, co-administration of the two peptides led to a marked additive reduction in food intake. Moreover, while OGTT-evoked blood glucose-excursions were significantly increased by ADM monotherapy, co-administration of ADM with a lower dose of GLP-1 normalized glucose excursions. In conclusion, we demonstrate additive anorectic effects of ADM and GLP-1, and that GLP-1 co-administration prevents ADM-induced impairment of glucose tolerance, suggesting that ADM could be potential anti-obesity target when combined with GLP-1 agonist therapy.

Original language	English
Journal	Biomedicine & Pharmacotherapy
Volume	109
Pages (from-to)	167-173
ISSN	0753-3322
DOIs	https://doi.org/10.1016/j.biopha.2018.10.040
Publication status	Published - Jan 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.biopha.2018.10.040Licence: CC BY-NC-ND

adrenomedullinFinal published version, 437 KBLicence: CC BY-NC-ND

Cite this

@article{1b61407561254794a33614bcaeb1f02e,

title = "Adrenomedullin and glucagon-like peptide-1 have additive effects on food intake in mice",

abstract = "Adrenomedullin (ADM) is a vasoactive peptide expressed in several peripheral organs and known primarily for its beneficial vasoactive effects. However, ADM is also known to inhibit insulin secretion, and central administration of ADM has been shown to elicit anorexigenic effects. Here, we investigated if peripheral co-administration of ADM and glucagon-like peptide 1 (GLP-1) could subdue the hypoglycaemic effects of ADM while enhancing its anorectic properties. The effects of mono- and combination therapy of ADM and GLP-1 on appetite regulation and glucose homeostasis were assessed acutely in male NMRI mice for 12 h, while effects on glucose homeostasis were assessed by oral glucose tolerance tests (OGTT). While the monotherapy with GLP-1 and ADM resulted in modest anorexigenic effects, co-administration of the two peptides led to a marked additive reduction in food intake. Moreover, while OGTT-evoked blood glucose-excursions were significantly increased by ADM monotherapy, co-administration of ADM with a lower dose of GLP-1 normalized glucose excursions. In conclusion, we demonstrate additive anorectic effects of ADM and GLP-1, and that GLP-1 co-administration prevents ADM-induced impairment of glucose tolerance, suggesting that ADM could be potential anti-obesity target when combined with GLP-1 agonist therapy.",

author = "Bech, {Esben M.} and Kristoffer Voldum-clausen and Pedersen, {S{\o}ren L.} and Katrine Fabricius and Rudkj{\ae}r, {Lise C.B.} and Hansen, {Henrik H.} and Jacob Jelsing",

year = "2019",

month = jan,

doi = "10.1016/j.biopha.2018.10.040",

language = "English",

volume = "109",

pages = "167--173",

journal = "Biomedicine & Pharmacotherapy",

issn = "0753-3322",

publisher = "Elsevier Masson",

}

TY - JOUR

T1 - Adrenomedullin and glucagon-like peptide-1 have additive effects on food intake in mice

AU - Bech, Esben M.

AU - Voldum-clausen, Kristoffer

AU - Pedersen, Søren L.

AU - Fabricius, Katrine

AU - Rudkjær, Lise C.B.

AU - Hansen, Henrik H.

AU - Jelsing, Jacob

PY - 2019/1

Y1 - 2019/1

N2 - Adrenomedullin (ADM) is a vasoactive peptide expressed in several peripheral organs and known primarily for its beneficial vasoactive effects. However, ADM is also known to inhibit insulin secretion, and central administration of ADM has been shown to elicit anorexigenic effects. Here, we investigated if peripheral co-administration of ADM and glucagon-like peptide 1 (GLP-1) could subdue the hypoglycaemic effects of ADM while enhancing its anorectic properties. The effects of mono- and combination therapy of ADM and GLP-1 on appetite regulation and glucose homeostasis were assessed acutely in male NMRI mice for 12 h, while effects on glucose homeostasis were assessed by oral glucose tolerance tests (OGTT). While the monotherapy with GLP-1 and ADM resulted in modest anorexigenic effects, co-administration of the two peptides led to a marked additive reduction in food intake. Moreover, while OGTT-evoked blood glucose-excursions were significantly increased by ADM monotherapy, co-administration of ADM with a lower dose of GLP-1 normalized glucose excursions. In conclusion, we demonstrate additive anorectic effects of ADM and GLP-1, and that GLP-1 co-administration prevents ADM-induced impairment of glucose tolerance, suggesting that ADM could be potential anti-obesity target when combined with GLP-1 agonist therapy.

AB - Adrenomedullin (ADM) is a vasoactive peptide expressed in several peripheral organs and known primarily for its beneficial vasoactive effects. However, ADM is also known to inhibit insulin secretion, and central administration of ADM has been shown to elicit anorexigenic effects. Here, we investigated if peripheral co-administration of ADM and glucagon-like peptide 1 (GLP-1) could subdue the hypoglycaemic effects of ADM while enhancing its anorectic properties. The effects of mono- and combination therapy of ADM and GLP-1 on appetite regulation and glucose homeostasis were assessed acutely in male NMRI mice for 12 h, while effects on glucose homeostasis were assessed by oral glucose tolerance tests (OGTT). While the monotherapy with GLP-1 and ADM resulted in modest anorexigenic effects, co-administration of the two peptides led to a marked additive reduction in food intake. Moreover, while OGTT-evoked blood glucose-excursions were significantly increased by ADM monotherapy, co-administration of ADM with a lower dose of GLP-1 normalized glucose excursions. In conclusion, we demonstrate additive anorectic effects of ADM and GLP-1, and that GLP-1 co-administration prevents ADM-induced impairment of glucose tolerance, suggesting that ADM could be potential anti-obesity target when combined with GLP-1 agonist therapy.

U2 - 10.1016/j.biopha.2018.10.040

DO - 10.1016/j.biopha.2018.10.040

M3 - Journal article

C2 - 30396073

SN - 0753-3322

VL - 109

SP - 167

EP - 173

JO - Biomedicine & Pharmacotherapy

JF - Biomedicine & Pharmacotherapy

ER -

Adrenomedullin and glucagon-like peptide-1 have additive effects on food intake in mice

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this